Greenwoods Asset Management Hong Kong Ltd. Sells 486,750 Shares of SPDR S&P Biotech ETF $XBI

Greenwoods Asset Management Hong Kong Ltd. decreased its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 87.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,265 shares of the exchange traded fund’s stock after selling 486,750 shares during the period. SPDR S&P Biotech ETF accounts for 0.2% of Greenwoods Asset Management Hong Kong Ltd.’s holdings, making the stock its 26th biggest position. Greenwoods Asset Management Hong Kong Ltd.’s holdings in SPDR S&P Biotech ETF were worth $8,324,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its position in SPDR S&P Biotech ETF by 27.3% in the third quarter. JPMorgan Chase & Co. now owns 13,538,738 shares of the exchange traded fund’s stock valued at $1,356,582,000 after purchasing an additional 2,900,633 shares during the period. Assetmark Inc. grew its holdings in shares of SPDR S&P Biotech ETF by 1,042,265.6% during the 4th quarter. Assetmark Inc. now owns 635,843 shares of the exchange traded fund’s stock worth $77,528,000 after purchasing an additional 635,782 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of SPDR S&P Biotech ETF by 123.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 872,796 shares of the exchange traded fund’s stock worth $72,542,000 after purchasing an additional 481,408 shares during the period. Marks Wealth LLC acquired a new stake in shares of SPDR S&P Biotech ETF during the 4th quarter worth about $28,857,000. Finally, Bessemer Group Inc. increased its position in shares of SPDR S&P Biotech ETF by 13.5% during the 4th quarter. Bessemer Group Inc. now owns 1,853,232 shares of the exchange traded fund’s stock worth $225,965,000 after purchasing an additional 220,244 shares during the last quarter.

SPDR S&P Biotech ETF Trading Down 0.7%

Shares of XBI opened at $126.79 on Wednesday. The company’s 50-day moving average price is $129.52 and its 200 day moving average price is $124.72. SPDR S&P Biotech ETF has a 12-month low of $78.00 and a 12-month high of $139.19. The firm has a market cap of $8.09 billion, a P/E ratio of 11.47 and a beta of 0.85.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.